Predictive potential of IL-28B genetic testing for interferon based hepatitis C virus therapy in Pakistan: Current scenario and future perspective

doi:10.4254/wjh.v8.i26.1116

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 8, Issue 26

This Article

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7877)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-1) series.

Item

Count

PDF

491

WORD

312

HTML

2985

Tables (1-1)

543

Sum=4331

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1299

Download

2254

Sum=3553

Sep 18, 2016 (publication date) through Mar 7, 2026

Times Cited of This Article

Times Cited (1)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Letter to the Editor

World J Hepatol. Sep 18, 2016; 8(26): 1116-1118
Published online Sep 18, 2016. doi: 10.4254/wjh.v8.i26.1116

Predictive potential of IL-28B genetic testing for interferon based hepatitis C virus therapy in Pakistan: Current scenario and future perspective

Muhammad Sohail Afzal

Muhammad Sohail Afzal, Department of Chemistry, School of Science, University of Management and Technology, Lahore 54000, Pakistan

Author contributions: Afzal MS designed the research, analyzed the data, wrote the letter, and revised the letter.

Conflict-of-interest statement: Afzal MS declares that there is no conflict of interest in this manuscript.

Correspondence to: Muhammad Sohail Afzal, PhD, Department of Chemistry, School of Science, University of Management and Technology, C-II Johar Town, Lahore 54000, Pakistan. sohail.ncvi@gmail.com

Telephone: +92-321-5244808

Received: April 5, 2016
Peer-review started: April 5, 2016
First decision: May 17, 2016
Revised: June 29, 2016
Accepted: July 20, 2016
Article in press: July 22, 2016
Published online: September 18, 2016
Processing time: 162 Days and 8.4 Hours

Core Tip

Core tip: Pakistan has a very heavy burden of hepatitis C virus (HCV) infection with around 11 million positive cases; however, in spite of well established prognostic value, the data regarding the role of interleukin 28B (IL-28B) single nucleotide polymorphisms (SNPs) in HCV antiviral therapy response are very limited. There are only six reports on the topic and it can be concluded from this limited information that IL-28B could be a good prognosis marker for HCV patient management in Pakistan. The major prevalent HCV genotype in Pakistan is 3a and IL-28B SNP rs12979860 showed a good prediction for interferon based antiviral therapy response against this viral genotype. It can be predicted that inclusion of IL-28B genetic testing in routine diagnostic set-up of Pakistan will help in better management of the disease. A well directed antiviral therapy based on personalized IL-28B genotyping along with virus genotyping will help in lessening of therapy cost and better management of the disease.